Brief: Innocare Says Unit Signs License Agreement With Zenas Biopharma
08/10/2025 09:57
Oct 8 (Reuters) - Innocare Pharma 688428.SS: SAYS UNIT SIGNS LICENSE AGREEMENT WITH ZENAS BIOPHARMA SAYS ZENAS WILL PAY COMPANY AN UPFRONT PAYMENT OF $100 MILLION, INCLUDING NEAR-TERM MILESTONE PAYMENTS SAYS TOTAL PAYMENTS ALONG WITH RESEARCH AND DEVELOPMENT, REGULATORY MILESTONE AND COMMERCIALIZATION MILESTONE PAYMENTS EXCEEDS $2 BILLION Source text Further company coverage: 688428.SS (Reporting by Hong Kong newsroom) ((donny.kwok@thomsonreuters.com; +852 3462 7745;))
Recent news on Zenas BioPharma
See all newsBrief: Zenas Biopharma Announces Upcoming Presentations Of Obexelimab Data In Igg4-Related Disease At The Igg4ward! 6Th International Symposium On Igg4-Related Disease And Acr Convergence 2026
Brief: Zenas BioPharma Files For Offering Of Up To 7.0 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing
Zenas BioPharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints